Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.28 -0.52 (-2.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Apellis Pharmaceuticals (NASDAQ:APLS) Fits the 'Affordable Growth' Investment Strategy ↗

January 22, 2026

Via Chartmill

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents a Compelling Growth and Technical Breakout Setup ↗

January 07, 2026

Via Chartmill

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Fits the 'Growth at a Reasonable Price' Strategy ↗

December 27, 2025

Apellis Pharmaceuticals exemplifies the GARP strategy with strong revenue growth, fair biotech valuation, and solid profitability margins.

Via Chartmill

Arteris Fortifies AI-Driven Future with Strategic Acquisition of Cycuity, Championing Semiconductor Cybersecurity

December 11, 2025

SAN JOSE, CA – December 11, 2025 – In a pivotal move poised to redefine the landscape of semiconductor design and cybersecurity, Arteris, Inc. (NASDAQ: APLS), a leading provider of system IP for...

Via TokenRing AI

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Emerges as a Prime GARP Investment ↗

December 06, 2025

Apellis Pharmaceuticals exemplifies the GARP strategy with strong commercial growth, recent profitability, and a valuation attractive relative to biotech peers.

Via Chartmill

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary ↗

August 18, 2025

Via Stocktwits

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity ↗

November 13, 2025

Discover Apellis Pharmaceuticals (APLS), an affordable growth stock with strong revenue growth, fair valuation, and solid financial health for investors.

Via Chartmill

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗

November 12, 2025

Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.

Via Benzinga

This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 06, 2025

Via Benzinga

These stocks are moving in today's session ↗

October 30, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

Here are the top movers in Thursday's session. ↗

October 30, 2025

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 30, 2025

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

October 30, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat ↗

October 30, 2025

Apellis Pharmaceuticals (APLS) Q3 2025 earnings crushed estimates, driven by strong drug sales and a major partnership payment. The company achieved profitability and positive market reaction.

Via Chartmill

Insights Ahead: Apellis Pharmaceuticals's Quarterly Earnings ↗

October 29, 2025

Via Benzinga

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts ↗

October 15, 2025

Via Benzinga

12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know ↗

September 26, 2025

During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent...

Via Benzinga

Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 26, 2025

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

Via Benzinga

Topics Stocks

Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket ↗

September 26, 2025

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of...

Via Benzinga

Topics Artificial Intelligence

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug ↗

July 31, 2025

Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from...

Via Stocktwits

Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗

July 31, 2025

Via Benzinga

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss ↗

July 31, 2025

Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for...

Via Chartmill

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio ↗

July 29, 2025

FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits.

Via Benzinga

Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals ↗

July 28, 2025

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.

Via Stocktwits

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗

July 18, 2025

Via Benzinga

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

July 02, 2025

Via Benzinga

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts ↗

May 22, 2025

Via Benzinga

Why Apellis Pharmaceuticals Wilted on Wednesday ↗

May 07, 2025

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.